Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

BioXcel Therapeutics (BTAI)

BioXcel Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:BTAI
DateTimeSourceHeadlineSymbolCompany
25/06/202412:00GlobeNewswire Inc.BioXcel Therapeutics Announces Positive Topline Results from Post-Marketing Requirement Study Evaluating PRN Treatment of IGALMI™ (dexmedetomidine) Sublingual Film for Agitation Associated with Bipolar Disorders or SchizophreniaNASDAQ:BTAIBioXcel Therapeutics Inc
19/06/202402:27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BTAIBioXcel Therapeutics Inc
19/06/202402:26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BTAIBioXcel Therapeutics Inc
19/06/202402:25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BTAIBioXcel Therapeutics Inc
19/06/202402:24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BTAIBioXcel Therapeutics Inc
17/06/202420:13Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BTAIBioXcel Therapeutics Inc
17/06/202419:34Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BTAIBioXcel Therapeutics Inc
17/06/202418:46Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BTAIBioXcel Therapeutics Inc
17/06/202418:04Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BTAIBioXcel Therapeutics Inc
12/06/202400:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BTAIBioXcel Therapeutics Inc
12/06/202400:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BTAIBioXcel Therapeutics Inc
04/06/202412:30Edgar (US Regulatory)Form 424B7 - Prospectus [Rule 424(b)(7)]NASDAQ:BTAIBioXcel Therapeutics Inc
28/05/202412:00GlobeNewswire Inc.BioXcel Therapeutics to Present at Jefferies Global Healthcare ConferenceNASDAQ:BTAIBioXcel Therapeutics Inc
21/05/202412:00GlobeNewswire Inc.BioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual MeetingNASDAQ:BTAIBioXcel Therapeutics Inc
09/05/202414:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BTAIBioXcel Therapeutics Inc
09/05/202412:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BTAIBioXcel Therapeutics Inc
09/05/202412:00GlobeNewswire Inc.BioXcel Therapeutics Reports First Quarter 2024 Financial ResultsNASDAQ:BTAIBioXcel Therapeutics Inc
25/04/202412:00GlobeNewswire Inc.BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024NASDAQ:BTAIBioXcel Therapeutics Inc
24/04/202415:30GlobeNewswire Inc.BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual MeetingNASDAQ:BTAIBioXcel Therapeutics Inc
22/04/202412:00GlobeNewswire Inc.BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market PotentialNASDAQ:BTAIBioXcel Therapeutics Inc
10/04/202412:00GlobeNewswire Inc.BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s DementiaNASDAQ:BTAIBioXcel Therapeutics Inc
25/03/202411:00GlobeNewswire Inc.BioXcel Therapeutics Announces $25 Million Registered Direct OfferingNASDAQ:BTAIBioXcel Therapeutics Inc
15/03/202411:00GlobeNewswire Inc.BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual DexmedetomidineNASDAQ:BTAIBioXcel Therapeutics Inc
12/03/202411:00GlobeNewswire Inc.BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023NASDAQ:BTAIBioXcel Therapeutics Inc
01/03/202412:00GlobeNewswire Inc.BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024NASDAQ:BTAIBioXcel Therapeutics Inc
14/02/202412:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BTAIBioXcel Therapeutics Inc
13/02/202414:00GlobeNewswire Inc.BioXcel Therapeutics Announces Termination of Proposed Public OfferingNASDAQ:BTAIBioXcel Therapeutics Inc
12/02/202417:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BTAIBioXcel Therapeutics Inc
12/02/202412:14GlobeNewswire Inc.BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)NASDAQ:BTAIBioXcel Therapeutics Inc
08/02/202422:27Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:BTAIBioXcel Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:BTAI

Your Recent History

Delayed Upgrade Clock